Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined effects of dapagliflozin and exenatide on food intake and brain reward/satiety circuits in obese patients with type 2 diabetes mellitus
2017-000841-28Phase 4Active
- Sponsor
- VU University Medical Center
- Start
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of exenatide and dapagliflozin in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by VU University Medical Center. Primary endpoint: Change in neuronal activity in central reward and satiety circuits by BOLD fMRI at 16 weeks. Started Aug 2017; status: active.
02
Drugs
exenatidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2017-000841-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000841-28.